Back to Journals » Cancer Management and Research » Volume 12

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date

Authors Sheng IY, Ornstein MC

Received 6 February 2020

Accepted for publication 26 May 2020

Published 23 June 2020 Volume 2020:12 Pages 4871—4881

DOI https://doi.org/10.2147/CMAR.S202017

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Beicheng Sun


Iris Y Sheng, Moshe C Ornstein

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Center Institute, Cleveland, OH, USA

Correspondence: Moshe C Ornstein Tel +1 216-445-6592
Fax +1 216-444-9464
Email ornstem@ccf.org

Abstract: Immunotherapy has revolutionized the management of metastatic renal cell carcinoma with four checkpoint inhibitors (nivolumab, ipilimumab, avelumab, and pembrolizumab) approved either as monotherapy or as combination therapy. The use of ipilimumab and nivolumab for treatment-naïve, intermediate to poor risk, metastatic renal cell carcinoma was the first checkpoint inhibitor-based combination therapy and remains the only dual checkpoint inhibitor combination approved in mRCC. In this article, we review the trials that led to the approval of ipilimumab and nivolumab in this setting. We also highlight the ongoing trials using this combination, its use in special populations, and clinically relevant unanswered questions.

Keywords: ipilimumab, nivolumab, metastatic renal cell carcinoma, immunotherapy, kidney cancer, checkpoint inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]